Saudi Journal of Otorhinolaryngology Head and Neck Surgery
Abstract Acute otitis media (AOM) represents a prevalent infection in children globally, leading to considerable morbidity and imposing a substantial burden on healthcare systems. Prompt and precise diagnosis is critical to reducing complications, such as tympanic membrane perforation, hearing impairment, and excessive antibiotic prescribing. Advances in artificial intelligence (AI), particularly deep learning, have created opportunities to enhance diagnostic accuracy and broaden access to care, especially in low-resource settings. This systematic review and meta-analysis aimed to evaluate the diagnostic performance of AI-based systems for detecting AOM compared with conventional clinical diagnosis and to analyze their accuracy relative to human clinicians across different model architectures and diagnostic methods. Following PRISMA-DTA standards and PROSPERO registration, systematic searches were conducted in PubMed, Web of Science, and IEEE Xplore up to July 30, 2025. Eligible studies included human participants with suspected AOM, employed AI-driven diagnostic approaches, and used a clinical reference standard. The Quality Assessment of Diagnostic Accuracy Studies-2 tool assessed bias, and pooled sensitivity and specificity were estimated using a bivariate random-effects model. Nine studies published between 2020 and 2025 met the inclusion criteria. The pooled sensitivity and specificity were 91% (95% confidence interval [CI]: 77%–97%) and 99% (95% CI: 94%–100%), respectively. AI models overall matched or outperformed general practitioners and pediatricians, approaching otolaryngologist-level accuracy. AI-based tools have the potential to improve AOM detection, mitigate inequalities in healthcare access, and promote more effective diagnosis, particularly in underserved regions.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).
SGLT2 inhibitorsheart failurepediatric heart failurechildren and adolescents
Purpose Graves’ ophthalmopathy (GO) is an autoimmune orbital inflammatory disease associated with Graves’ disease. It can cause vision loss, facial disfigurement, and reduced quality of life. Systemic corticosteroids remain the first-line treatment for moderate-to-severe GO, administered either orally or intravenously. However, the optimal route of administration remains uncertain, with ongoing debate regarding their comparative efficacy and safety.The aim of this review is to compare the efficacy and safety of intravenous versus oral corticosteroids in the treatment of moderate-to-severe GO.Methods Randomized controlled trials were included. Risk of bias was assessed using the Cochrane RoB 2 tool. Outcomes focused on efficacy and safety of intravenous versus oral glucocorticoids in the treatment of GO.Results Five eligible RCTs involving 288 patients were analyzed. Intravenous steroids appeared to improve the clinical activity score (MD = −0.57; 95% CI: −0.82 to −0.33; p < 0.00001) and reduce the risk of Cushingoid facial features (RR = 0.17; 95% CI: 0.08 to 0.35; p < 0.00001). However, limited efficacy was observed in diplopia, proptosis, and in minimizing other steroid-related adverse events.Conclusion IV steroids were associated with more favourable outcomes and better tolerability than oral steroids in moderate-to-severe GO. Further comprehensive trials are needed to confirm long-term safety and optimize treatment protocols.
Objective This study evaluated the impact of adenotonsillectomy on asthma symptoms in children by combining observational evidence with pooled analysis.Data sources We searched MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, Web of Science, ProQuest, and Scopus from inception to March 17, 2025.Study selection Eligible studies assessed asthma outcomes in children undergoing adenotonsillectomy using retrospective or prospective cohort designs, case series, or database analyses. Eleven studies involving 74,204 participants were identified. Outcomes included asthma control scores (ACT/cACT), acute asthma exacerbations (AAEs), emergency department (ED) visits, oral corticosteroid use, hospitalization, inflammatory biomarkers, and atopic risk. Risk of bias was evaluated using ROBINS-I.Results Meta-analysis incorporated five studies with 52,479 participants. Adenotonsillectomy improved ACT/cACT scores by a mean of 2.5 points (95% CI:1.6–3.4; I2=0%), indicating better asthma control. A reduced risk of AAEs was observed (RD = 0.29; 95% CI:0.01–0.58), though with extreme heterogeneity (I2=100%). ED visits showed a small but significant reduction (MD=–0.01; 95% CI:0.00–0.02; I2=0%). Narrative synthesis found corticosteroid courses decreased by 23.7%, hospitalization rates fell by up to 35.8%, and patients reported improved quality of life and lower inflammatory biomarkers. However, most studies carried moderate to severe risk of bias due to confounding and selection issues.Conclusions Adenotonsillectomy may improve asthma control, reduce ED visits, and lessen medication use and hospitalization among children. Evidence regarding its effect on exacerbations remains inconsistent, and causality cannot be inferred due to reliance on observational data. Well-designed prospective controlled trials are needed to confirm effectiveness and clarify underlying mechanisms.
Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.
The Journal of Sports Medicine and Physical Fitness · مجلد 65 (1) · 117-124
INTRODUCTION: The FIFA 11+ preventive program is designed to reduce the incidence of injury in sports. However, to gain a better understanding of its effect a systematic review and meta-analysis is needed. The current review aims to investigate the effect of the FIFA 11+ preventive program on injury incidence among male and female football players. EVIDENCE ACQUISITION: This study used Scopus, PEDro, SPORTDiscus, and ProQuest as data sources. The initial selection of the studies, thorough assessment of the tile, and abstract. Extraction of the necessary study data was conducted by two independent researchers. Another two independent researchers assessed the quality of each included study against 39 used criteria. These criteria were combined from several popular quality assessment scales. The incidence of injuries measured in the lower extremities in football players after addressing the FIFA11+ was the outcome of interest. EVIDENCE SYNTHESIS: This review included 12 trials of variable methodological quality from which 10 trials were selected for the meta-analysis. In general, the FIFA11+ program showed a significant reduction (P<0.1) in lower limb injury incidence for male young and adults in comparison to other programs. However, evidence of its effectiveness in females is lacking and more studies are needed. CONCLUSIONS: The FIFA 11+ program is recommended to be used and implemented as a preventive strategy in males. Although, the result showed a significant reduction in injury incidence in adult males, heterogeneity between studies is high which may reduce the generalizability of the results. More studies are needed to investigate the effect of the FIFA 11+ program on females.
FIFA 11+injury preventionlower limb injuriesfootball players
Journal of Neurosurgery Spine · مجلد 40 (5) · 653-661
OBJECTIVE: The objective was to evaluate the efficacy, outcomes, and complications of surgical intervention performed within 24 hours (≤ 24 hours) versus after 24 hours (> 24 hours) in managing acute traumatic central cord syndrome (ATCCS). METHODS: Articles pertinent to the study were retrieved from PubMed, Scopus, Web of Science, and Cochrane. The authors performed a systematic review and meta-analysis of treatment procedures and outcomes according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines. RESULTS: Seven articles comprising 488 patients were included, with 188 (38.5%) patients in the ≤ 24-hour group and 300 (61.5%) in the > 24-hour group. Significant differences were not found between groups in terms of demographic characteristics, injury mechanism, spinal cord compression level, neuroimaging features, and the American Spinal Injury Association (ASIA) motor score at admission. Both groups had a similar approach to surgery and steroid administration. The surgical complication rate was significantly higher in the > 24-hour group (4.5%) compared to the ≤ 24-hour group (1.2%) (p = 0.05). Clinical follow-up duration was similar at 12 months (interquartile range 3-36) for both groups (p > 0.99). The ≤ 24-hour group demonstrated a not statistically significant greater improvement in ASIA motor score, with a mean difference of 12 (95% CI -20.7 to 44.6) compared to the > 24-hour group. CONCLUSIONS: The present study indicates potential advantages of early (≤ 24 hours) surgery in ATCCS patients, specifically in terms of lower complication rates. However, further research is needed to confirm these findings and their clinical implications.
spinal cord injurytiming of surgeryearly surgical interventiondelayed surgery